Novo Nordisk A/S (NYSE:NVO) Stake Raised by DecisionMap Wealth Management LLC

DecisionMap Wealth Management LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 29.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,366 shares of the company’s stock after acquiring an additional 1,661 shares during the period. DecisionMap Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $512,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of NVO. GQG Partners LLC lifted its stake in Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $404,910,000. Loomis Sayles & Co. L P lifted its stake in Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Nuveen Asset Management LLC lifted its stake in Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock worth $537,189,000 after acquiring an additional 2,639,693 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $158,657,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 0.4%

Shares of NYSE NVO opened at $74.03 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The business’s 50-day simple moving average is $68.23 and its 200-day simple moving average is $78.93. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NVO. BMO Capital Markets reaffirmed a “market perform” rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, June 14th. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Finally, Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.